Talphera (TLPH) Current Deferred Revenue (2013 - 2022)
Talphera's (TLPH) quarterly Current Deferred Revenue came in at $1.2 million in Q4 2022, down 6.95% year-on-year from $1.2 million in Q4 2021, and down 3.6% quarter-over-quarter from $1.2 million in Q3 2022.
Talphera (TLPH) Current Deferred Revenue (2013 - 2022) Analysis & Trends
Talphera's Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $1.2 million for Q4 2022.
- On a quarterly basis, Current Deferred Revenue fell 6.95% year-over-year to $1.2 million in Q4 2022; TTM through Dec 2022 was $1.2 million, a 6.95% decrease from a year earlier, with the FY2022 full-year figure at $1.2 million, down 6.95% from the prior year.
- Current Deferred Revenue declined to $1.2 million in Q4 2022 per TLPH's latest filing, from $1.2 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $3.3 million in Q2 2019 and bottomed at $49000.0 in Q4 2020.
- The 5-year median for Current Deferred Revenue is $424000.0 (2019), against an average of $939222.2.
- Across the five-year window, Current Deferred Revenue plunged 98.49% in 2020 and surged 2424.49% in 2021, its largest moves.
- Year by year, Current Deferred Revenue stood at $315000.0 in 2018, then surged by 929.84% to $3.2 million in 2019, then plunged by 98.49% to $49000.0 in 2020, then jumped by 2424.49% to $1.2 million in 2021, then fell by 6.95% to $1.2 million in 2022.
- Per Business Quant, the three latest TLPH Current Deferred Revenue figures stand at $1.2 million (Q4 2022), $1.2 million (Q3 2022), and $1.2 million (Q2 2022).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Talphera | 47.31 Mn | 9.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 1.15 Mn |
| Sep 30, 2022 | 1.19 Mn |
| Jun 30, 2022 | 1.21 Mn |
| Mar 31, 2022 | 1.24 Mn |
| Dec 31, 2021 | 1.24 Mn |
| Sep 30, 2021 | 1.24 Mn |
| Dec 31, 2020 | 49,000.00 |
| Sep 30, 2020 | 200,000.00 |
| Jun 30, 2020 | 343,000.00 |
| Mar 31, 2020 | 411,000.00 |
| Dec 31, 2019 | 3.24 Mn |
| Sep 30, 2019 | 315,000.00 |
| Jun 30, 2019 | 3.31 Mn |
| Mar 31, 2019 | 437,000.00 |
| Dec 31, 2018 | 315,000.00 |
| Sep 30, 2018 | 326,000.00 |
| Jun 30, 2018 | 338,000.00 |
| Mar 31, 2018 | 350,000.00 |
| Dec 31, 2017 | 362,000.00 |
| Sep 30, 2017 | 362,000.00 |